JP2004516013A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516013A5
JP2004516013A5 JP2002514188A JP2002514188A JP2004516013A5 JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5 JP 2002514188 A JP2002514188 A JP 2002514188A JP 2002514188 A JP2002514188 A JP 2002514188A JP 2004516013 A5 JP2004516013 A5 JP 2004516013A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
nucleic acid
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002514188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516013A (ja
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/en
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/en
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/en
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,208 external-priority patent/US7217412B2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Application filed filed Critical
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Publication of JP2004516013A publication Critical patent/JP2004516013A/ja
Publication of JP2004516013A5 publication Critical patent/JP2004516013A5/ja
Withdrawn legal-status Critical Current

Links

JP2002514188A 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法 Withdrawn JP2004516013A (ja)

Applications Claiming Priority (36)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US22062400P 2000-07-25 2000-07-25
US22066400P 2000-07-25 2000-07-25
PCT/US2000/020710 WO2001009327A2 (en) 1999-07-28 2000-07-28 Method of preventing the injury or death of retinal cells and treating ocular diseases
US22269500P 2000-08-02 2000-08-02
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
PCT/US2000/023522 WO2001016319A2 (en) 1999-08-31 2000-08-23 Compositions and methods for the treatment of immune related diseases
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US23097800P 2000-09-07 2000-09-07
US66461000A 2000-09-18 2000-09-18
US66535000A 2000-09-18 2000-09-18
US24292200P 2000-10-24 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (en) 2000-01-06 2000-11-08 Methods and compositions for inhibiting neoplastic cell growth
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/034956 WO2001046420A2 (en) 1999-12-23 2000-12-20 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US79649801A 2001-02-28 2001-02-28
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases
US80270601A 2001-03-09 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017443 WO2002016611A2 (en) 2000-08-24 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2008194721A Division JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Division JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Division JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Division JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Publications (2)

Publication Number Publication Date
JP2004516013A JP2004516013A (ja) 2004-06-03
JP2004516013A5 true JP2004516013A5 (enrdf_load_stackoverflow) 2010-07-15

Family

ID=56290165

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002514188A Withdrawn JP2004516013A (ja) 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Country Status (5)

Country Link
EP (1) EP1309685A2 (enrdf_load_stackoverflow)
JP (5) JP2004516013A (enrdf_load_stackoverflow)
AU (1) AU2001271973A1 (enrdf_load_stackoverflow)
CA (1) CA2416538A1 (enrdf_load_stackoverflow)
WO (1) WO2002008284A2 (enrdf_load_stackoverflow)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1999012963A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US20030187196A1 (en) 1998-12-30 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
PT1992695E (pt) 1999-08-12 2011-01-12 Agensys Inc Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
EP1637541B1 (en) * 1999-09-01 2010-03-03 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1228208T3 (da) 1999-10-28 2010-11-22 Agensys Inc 36P6D5: udskilt tumorantigen
EP1897946B1 (en) * 1999-12-23 2012-07-11 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
PT1283214E (pt) * 2000-04-21 2007-03-30 Fuso Pharmaceutical Ind Novas colectinas
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2792747A1 (en) * 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7115415B2 (en) 2000-09-15 2006-10-03 Genentech, Inc. PRO9821 nucleic acids
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US20060141453A9 (en) 2000-11-03 2006-06-29 Qun-Yong Zhou Prokineticin polypeptides, related compositions and methods
WO2002040654A2 (en) 2000-11-14 2002-05-23 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003215761A1 (en) * 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003220805A1 (en) * 2002-03-28 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
JP2005536190A (ja) * 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2004022087A1 (ja) * 2002-09-04 2004-03-18 Takeda Pharmaceutical Company Limited 疾患関連遺伝子の用途
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2006513700A (ja) * 2002-09-25 2006-04-27 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
KR101294959B1 (ko) 2003-03-12 2013-08-09 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의 용도
DK2784084T4 (da) 2003-07-08 2024-01-08 Novartis Pharma Ag Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
NZ550110A (en) 2004-04-14 2009-09-25 Genentech Inc Compositions and methods comprising an EGFL7 antagonist for modulating vascular development
PT1781682E (pt) 2004-06-24 2013-05-14 Mayo Foundation B7-h5, um polipéptido coestimulante
KR20070036089A (ko) 2004-07-02 2007-04-02 제넨테크, 인크. 비호지킨 림프종의 치료 방법 및 치료 조성물
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
BRPI0820387A2 (pt) * 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR101508086B1 (ko) 2008-05-05 2015-04-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
RU2015117054A (ru) 2008-05-06 2015-10-20 Дженентек, Инк. ВАРИАНТЫ CRIg С СОЗРЕВШЕЙ АФФИНОСТЬЮ
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
SG175891A1 (en) 2009-05-08 2011-12-29 Genentech Inc Humanized anti-egfl7 antibodies and methods using same
AT508569A1 (de) * 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
KR102126964B1 (ko) 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
SI3026064T1 (sl) 2011-05-13 2019-03-29 Ganymed Pharmaceuticals Gmbh Protitelesa za zdravljenje raka, ki eksprimira klavdin 6
EP3597666A3 (en) 2011-07-01 2020-04-22 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN110922467A (zh) * 2013-01-17 2020-03-27 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
BR112016009099A2 (pt) 2013-10-28 2017-09-19 Ngm Biopharmaceuticals Inc Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
CA2937898A1 (en) 2014-01-24 2015-07-30 Ngm Biopharmaceuticals, Inc. Antibodies that bind to beta klotho and uses thereof
TW201623337A (zh) 2014-05-01 2016-07-01 建南德克公司 抗－因子ｄ抗體變異體及其用途
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2000053756A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999010363A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. 29 human secreted proteins
JP2002506615A (ja) * 1998-02-27 2002-03-05 財団法人相模中央化学研究所 膜貫通ドメインを有するヒト蛋白質とそれをコードするｄｎａ
NZ507435A (en) * 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
JP2002509722A (ja) * 1998-03-31 2002-04-02 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
CA2341767A1 (en) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
EP1135485B1 (en) * 1998-12-01 2010-02-17 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU2399300A (en) * 1999-03-08 2000-09-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제

Similar Documents

Publication Publication Date Title
JP2004516013A5 (enrdf_load_stackoverflow)
EP0617126B1 (en) Polypeptide capable of inhibiting the binding between human IL-6 and its receptor
EP3760642A1 (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
HK1218554A1 (zh) 人pac1抗體
JPS626000A (ja) ハイブリドインタ−フエロン及びその製造方法
JP4308322B2 (ja) インターフェロンアルファ／ベータ受容体に対する抗体
JP2004513876A (ja) 抗−腫瘍剤としてのｔａｃｉ
BG107613A (bg) Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена
US6627439B2 (en) Antibodies against SEMP1(p23)
JP2020509737A5 (enrdf_load_stackoverflow)
JP2008508858A (ja) マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
CN111018987A (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
KR102669444B1 (ko) Etar 항체 및 이의 약학 조성물 및 용도
TW202108630A (zh) ETA抗體與TGF-β Trap的融合蛋白質，以及其藥物組合物和應用
TW416960B (en) Reshaped human antibody to human interleukin-8
JP2003530871A (ja) インテグリン／接着因子アンタゴニスト
EP1283217B1 (en) Antibodies against the IL-8 receptor, and their therapeutic uses
KR100277769B1 (ko) 항-파스 재조합 항체 및 이에 대한 디엔에이
WO2006046661A1 (ja) インターロイキン－６阻害剤
US20240400658A1 (en) Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
CN119421903A (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
JP7300008B2 (ja) 低免疫原性かつ低ＡＤＣＣ／ＣＤＣ機能の抗ＴＮＦ－αヒト化モノクローナル抗体ＴＣＸ０６０およびその使用
WO2020248967A1 (zh) Eta抗体与bnp的融合蛋白质，以及其药物组合物和应用